Cairo: SPE Capital Partners (“SPE”) and Future Pharmaceutical Industries (“FPI”) are pleased to announce the signature, on March 21st, of binding agreements in relation with an equity investment by SPE AIF I, a private equity fund managed by SPE Capital, in FPI, sealing their partnership and materializing discussions that took place over the past year.
FPI, founded in 2007 and led by its founder and Chairman, Dr Gamal El Leithy, is among the fastest growing branded generic pharmaceuticals manufacturers in Egypt. With its state-of-the-art facility, FPI has developed an unmatched expertise in manufacturing high quality generics. The company has significantly increased its market share in the growing Egyptian pharmaceutical sector and enjoys a great reputation of quality and of manufacturing excellence. FPI also stands as the manufacturing partner of choice for renowned multinational industry leaders such as Sanofi and Novartis.
The partnership between FPI and SPE aims to enable the company to accelerate its growth, invest in new lines to produce new forms and develop export markets over the next years.
Commenting on the partnership, Dr El Leithy said: “Our growth has been accelerating over the past years and we felt this is the right time to have an institutional investor like SPE join us to support our fast growth and help institutionalize the company. We have great plans for FPI for the years to come and look forward to combining our strengths with those of SPE to materialize them.”
Mehdi Charfi, Managing Partner who led the transaction on behalf of SPE said: “This is our second investment in the Egyptian pharmaceutical sector, after a first successful investment over 2013-2017. We believe the pharmaceutical sector in Egypt has strong fundamentals of growth and resilience. Within the sector, players with solid management, manufacturing excellence and strong marketing know-how, like FPI, can significantly outperform the market. Today, we are happy and excited to join forces with Dr Gamal El Leithy to take FPI to the next level.”
Closing of the transaction is subject to the satisfaction of customary closing conditions and is expected to take place before mid-year.
About SPE Capital
SPE Capital is a private equity firm formed in 2016 from a spinout from Swicorp, a leading regional investment banking firm. The SPE Capital team has invested over USD 1 billion since 2005, across Africa and the Middle East. SPE Capital is led by an experienced investment team, with a combined experience of more than 60 years investing in growth companies.
About Future Pharmaceutical Industries
Established in 2007 in Egypt, FPI is a pharmaceutical company engaged in the manufacturing and the marketing of own branded generic medicine as well as the manufacturing for third parties including multinational pharmaceutical firms such as Novartis or Sanofi.
Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
